

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Shanghai Haohai Biological Technology Co., Ltd.*

上海昊海生物科技股份有限公司

(a joint stock company incorporated in the People's Republic of China with limited liability)

(Stock code: 6826)

PROPOSED AMENDMENTS TO THE ARTICLES OF ASSOCIATION AND THE ABOLISHMENT OF THE SUPERVISORY COMMITTEE

This announcement is made by Shanghai Haohai Biological Technology Co., Ltd.* (the “**Company**”) pursuant to Rule 13.51(1) of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Hong Kong Stock Exchange**”).

In accordance with the Company Law of the People's Republic of China (the “**Company Law**”), and the Guidelines to the Articles of Association of Listed Companies (《上市公司章程指引》) and Rules for Shareholders' Meetings of Listed Companies (《上市公司股東會規則》) and other relevant provisions recently revised by the China Securities Regulatory Commission, the responsibilities of the supervisory committee of a listed company will transition to the audit committee, and the role of supervisors will no longer be mandatory. In addition, the Consultation Conclusions on Proposals to Further Expand the Paperless Listing Regime and Other Rule Amendments (《建議進一步擴大無紙化上市機制及其他<上市規則>修訂的諮詢總結》), which is published by the Hong Kong Stock Exchange in January 2025, adopted the proposals on hybrid shareholders' meeting and electronic voting, requiring issuers to ensure that their articles of association allow them to hold hybrid shareholders' meeting and provide for electronic voting on or before the first annual general meeting held after 1 July 2025.

In accordance with the provisions of the aforesaid laws, regulations and regulatory documents and the relevant amendments, and taking into account the actual operational and management needs of the Company, the Company proposes to amend the Articles of Association of the Company (“**Articles of Association**”) and abolish the supervisory committee of the Company, subject to the approval by the shareholders for the amendments to the Articles of Association. The relevant responsibilities of the supervisory committee will be exercised by the audit committee of the Company. The Rules of Procedure of the Supervisory Committee of the Company and other related governance documents shall be repealed accordingly.

In light of the aforementioned situations, the Rules of Procedure of the General Meeting of the Company (the “**Rules of Procedure of the General Meeting**”) and the Rules of Procedure of the Board of the Company (the “**Rules of Procedure of the Board**”) are proposed to be amended to align with the proposed amendments to the Articles of Association (collectively referred to as the “**Proposed Amendments**”).

The Proposed Amendments to the Articles of Association, the Rules of Procedure of the General Meeting and the Rules of Procedure of the Board are respectively set out in Appendix VI, Appendix VII and Appendix VIII of the circular to the Company's 2024 annual general meeting (the "AGM"), which is announced simultaneously with this announcement. Save for the Proposed Amendments, there are no substantive amendments to other provisions in the Articles of Association, the Rules of Procedure of the General Meeting and the Rules of Procedure of the Board. The non-substantial amendments include adjustments to the numbering of clauses of the Articles of Association and that involved in cross-referencing due to the addition or deletion of certain clauses, as well as the uniform modification of the expression "general meeting" to "shareholders' meeting" in accordance with the Company Law, which will not be listed item by item.

In accordance with the Articles of Association and relevant laws and regulations, the Proposed Amendments are subject to approval by special resolutions of the shareholders at a general meeting. A circular containing, among others, details of the Proposed Amendments and a notice of the AGM are published on the websites of Hong Kong Stock Exchange (www.hkexnews.hk) and the Company's website (www.3healthcare.com) on 9 May 2025.

By order of the Board
Shanghai Haohai Biological Technology Co., Ltd.*
Hou Yongtai
Chairman

Shanghai, the PRC, 9 May 2025

As at the date of this announcement, the executive directors of the Company are Dr. Hou Yongtai, Mr. Wu Jianying, Ms. Chen Yiyi and Mr. Tang Minjie; the non-executive directors of the Company are Ms. You Jie and Mr. Huang Ming; and the independent non-executive directors of the Company are Mr. Shen Hongbo, Mr. Jiang Zhihong, Mr. Su Zhi, Mr. Yang Yushe and Mr. Zhao Lei.

* *For identification purpose only*